Brands Set Sights On Lame-Duck Session After Opioid Bill Excludes Part D Deal

By John Wilkerson Ariel Cohen / September 26, 2018 at 11:00 AM
The final version of opioid legislation excludes brand-drug industry-backed Part D changes, and now brand lobbyists have set their sights on the lame-duck session for getting Congress to lower the industry’s share of seniors’ drug costs. Republican and Democratic lawmakers released the final version of opioids legislation late Tuesday night (Sept. 25), just in time to allow a vote on Thursday as lawmakers scramble to get back to their districts to campaign. The Pharmaceutical Research and Manufacturers of America sought...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.